ESMO Preceptorship on Uterine Cancer 2024: Lugano
Do not miss this opportunity: apply now!
ESMO Breast Cancer 2024
Meet us in Berlin and listen to bright minds share their expertise and vision for the future of the breast cancer field
European Society For Medical Oncology
Taxonomy of Tumour-agnostic Therapeutics Webinar
Stay up to date with the latest ESMO recommendations on precision medicine for its optimal integration into daily care with this new webinar series
Digital Health as Cancer Care Facilitator
Secure your place for the second webinar in this new, vibrant series and learn how standardised primary data can improve patient outcomes.
ESMO Gastrointestinal Cancers Congress 2024
Members of the ESMO GI 2024 Scientific Committee and global gastrointestinal cancers experts provide compelling reasons why attending this event is crucial.
ESMO Academy 2024
Registration for the ESMO Academy 2024 is now open. Get your update on the key topics in medical oncology.
Venous Thromboembolism in Cancer Patients Webinar
How to apply the latest, best practice recommendations to your daily practice? Join this live discussion and have your questions answered by the experts developing and implementing the ESMO Guidelines
ESMO Asia 2024
This annual congress, specifically focused on multidisciplinary oncology in the Asian region, is the place to showcase the latest research findings in the field.
Lymphomas: Essentials for Clinicians, Third Edition
This updated edition provides an up-to-date overview of the current treatment options and what future developments are on the horizon in the fast-developing field of lymphomas.
ESMO Preceptorship on Gastric Cancer, 27-28 September 2024, Lisbon, Portugal
Online application is open until 5 June 2024
Updated treatment algorithms
The living guideline is directly linked to ESMO-MCBS scores and references, easily accessible on desktop and mobile devices
ESMO-MCBS
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
HER2-positive Early Breast Cancer
Access the resources for this in-depth discussion with the specialists in the field to know about hot topics and future trends
Latest News
EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab
Wyost is highly similar to the reference product Xgeva which was authorised in the EU in 2011
A Novel Model Helps Better Predict Risk of Cancer Development in Patients with Li-Fraumeni Syndrome
Better risk counselling may be achieved using the mathematical model
Liquid biopsy: may ctDNA tumour fraction help interpret negative results?
A study illustrates a methodology that shows promise to distinguish true negative liquid biopsy results from indeterminate results that may benefit from follow-up tissue testing
FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-positive Solid Tumours
Evidence for efficacy is based on the results from the DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 studies
Favourable Response More Likely with Neoadjuvant Dual Immune Checkpoint Inhibitor Than with Anti-PD1 Therapy Alone, but the Occurrence of Adverse Events Is Also Higher
Findings from a pooled analysis of clinical trials conducted in patients with high-risk resectable melanoma
Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in Patients with Resectable NSCLC and Tumour PD-L1 Less Than 1%
Findings from a systematic review and meta-analysis
Early breast cancer: higher quality of life reported with a personalised follow-up
A nurse-led follow-up strategy including self-management interventions, use of patient-reported outcomes and phone consultations also resulted in lower fear of recurrence, anxiety and depression
FDA Approves Mirvetuximab Soravtansine-gynx for FRα-positive, Platinum-resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Evidence for efficacy is based on the results from the MIRASOL study
ESMO Submits Feedback to the European Observatory on Health Systems and Policies (EOHSP) Stakeholder Survey on EU Health Priorities for the Next European Commission’s Mandate (2024-2029)
Optimisation of EU healthcare workforce, further commitment to achieving Universal Health Coverage (UHC) and improved performance and resilience of EU health systems must become a top policy priority for the next EU mandate to ensure sustainable cancer care services for all
EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab
Wyost is highly similar to the reference product Xgeva which was authorised in the EU in 2011
A Novel Model Helps Better Predict Risk of Cancer Development in Patients with Li-Fraumeni Syndrome
Better risk counselling may be achieved using the mathematical model
FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-positive Solid Tumours
Evidence for efficacy is based on the results from the DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 studies
Favourable Response More Likely with Neoadjuvant Dual Immune Checkpoint Inhibitor Than with Anti-PD1 Therapy Alone, but the Occurrence of Adverse Events Is Also Higher
Findings from a pooled analysis of clinical trials conducted in patients with high-risk resectable melanoma
Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in Patients with Resectable NSCLC and Tumour PD-L1 Less Than 1%
Findings from a systematic review and meta-analysis
FDA Approves Mirvetuximab Soravtansine-gynx for FRα-positive, Platinum-resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Evidence for efficacy is based on the results from the MIRASOL study
Omission of Completion Axillary Lymph Node Dissection Noninferior to More Extensive Surgery in Patients with Breast Cancer Sentinel-Node Macrometastases
Findings from the SENOMAC study
A PET-based, pCR-adapted Chemotherapy De-escalation Strategy Associated with an Excellent 3-year iDFS Among Patients with HER2-positive Early Breast Cancer
Findings from the PHERGain study
Oxaliplatin-Based Adjuvant Chemotherapy Shows Good Tolerance and Similar Time To Recurrence In Trial-Fit Older Compared with Younger Patients with Stage III Colon Cancer
Findings from an ACCENT/IDEA pooled analysis of 12 adjuvant trials
European Lung Cancer Congress 2024
The European Lung Cancer Congress 2024 is the annual appointment that brings together various experts in the field of thoracic oncology
ESMO Sarcoma and Rare Cancers Congress 2024
The ESMO Sarcoma and Rare Cancers Congress 2024 will be held in Lugano from 14 to 16 March and will bring together world-renowned experts among researchers and practitioners, to present and discuss the latest advances in the treatment and care of sarcoma and rare cancers in general
ESMO Targeted Anticancer Therapies Congress 2024, 26-28 February, Paris, France
The ESMO Targeted Anticancer Therapies Congress 2024 is the annual multi-stakeholder meeting that focuses on the development of novel anticancer therapies and how this can transform the current knowledge and impact clinical care
Obesity and Alcohol Are Contributing to Increases in Bowel Cancer Rates among Young Adults
Experts predict death rates from all cancers for the EU and UK for 2024
ESMO Immuno-Oncology Congress 2023, 6-8 December 2023, Geneva, Switzerland
The ESMO Immuno-Oncology Congress 2023, where experts discuss the latest scientific developments in this fast-moving field of cancer treatment, will be held in Geneva, Switzerland, between 6-8 December, also with a virtual component
ESMO Asia Congress 2023, 1-3 December 2023, Singapore
The ESMO Asia Congress 2023 is the annual meeting to present and discuss the latest scientific and clinical advances across the entire field of oncology, of relevance at a global level and specifically for the Asia-Pacific region.
ESMO Manifesto - Translating Scientific Evidence Into Effective Public Health Policy
Evidence is building up that strong political action has the potential to tackle two of our era’s biggest challenges: climate change and the increasing burden of cancer on society
The Right to be Forgotten: ESMO Calls on EU Countries to Ensure Equal Financial Rights for Cancer Survivors
As the ESMO Congress 2023 opens its doors in Madrid this week, ESMO calls all EU member states to act on the recently adopted final text of the EU Consumer Credits Directive by following their European neighbours Spain and France and guaranteeing cancer survivors seeking financial credit the so-called right to be forgotten after a period of five years following the end of their treatment
Advances in Gynaecological Cancer Research Could Change the Treatment Landscape
Results from highly anticipated phase 3 clinical trials in gynaecological cancers with, among others, new data that cover the entire spectrum of managing patients with cervical cancer, will be presented at the ESMO Congress 2023 in Madrid, Spain
2024 ESMO Breast Cancer Award Recipient Announced
The European Society for Medical Oncology (ESMO) announced today that the 2024 ESMO Breast Cancer Award is conferred to Hope S. Rugo, Professor of Medicine and Winterhof Family Professor of Breast Cancer at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
2024 Heine H. Hansen Award Recipient Announced
The European Society for Medical Oncology (ESMO) announced today that the 2024 Heine H. Hansen Award is bestowed to Enriqueta Felip
Nomination Process for the 2024 ESMO Society Awards Now Open
The nomination process for the 2024 ESMO Society Awards is now open
ESMO Committees and Working Groups: New Chair Appointments
ESMO is pleased to announce the newly appointed Committee and Working Group Chairs who started their mandates in January 2024
2024 TAT Honorary Award Recipient Announced
The European Society for Medical Oncology (ESMO) has announced today that the 2024 ESMO TAT Honorary Award is bestowed to Funda Meric-Bernstam
ESMO releases twenty-three new statements on COVID-19 vaccination in people with cancer
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO partners with the Lancet Commission on Women and Cancer to advancing gender equity in cancer
ESMO President will act as an Advisor
ESMO’s Special Status as Non-State Actor in Official Relations with WHO Has Been Renewed
ESMO is pleased to announce the renewal of its status as non-State actor in official relations with the World Health Organization - a privilege granted to non-governmental organisations, which recognises ESMO’s sustained and systematic engagement in the interest of the WHO
The ESMO Manifesto: Outlining Key Areas to Unleash the Potential of the EU Beating Cancer Plan
An evidence-based and patient-centred approach to close the care gap for a healthier Europe
Liquid biopsy: may ctDNA tumour fraction help interpret negative results?
A study illustrates a methodology that shows promise to distinguish true negative liquid biopsy results from indeterminate results that may benefit from follow-up tissue testing
Early breast cancer: higher quality of life reported with a personalised follow-up
A nurse-led follow-up strategy including self-management interventions, use of patient-reported outcomes and phone consultations also resulted in lower fear of recurrence, anxiety and depression
Research in upper gastrointestinal cancers makes a leap forward
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
Colorectal cancer screening: performance of a blood-based test is promising
A study reports high sensitivity and specificity of a cell-free DNA blood-based assay compared to colonoscopy
Health as a human right, cancer care as a human priority
Universal health coverage in oncology is still not a reality, as a recent report shows
A study shows correlation between fatty acids intake and response to immunotherapy
Dietary regimens may alter the microbiome composition, increasing bacteria with a beneficial immunogenic effect
Concomitant immunotherapy plus chemoradiotherapy does not improve outcomes in advanced lung cancer
A study reports no significant survival benefits with the concurrent treatment with durvalumab in patients with unresectable stage III NSCLC
Are ADCs in lung cancer living up to expectations?
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC
Incorporating ctDNA into clinical trial design
ctDNA offers immense possibilities for improving the management of early-stage lung cancer and the area is primed for new trials to test this approach in the context of minimal residual disease
Education
Provide your patients with the best care options.
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
ESMO Courses
The courses include state of the art lectures, workshops and interactive discussion seminars
ESMO Oncology Journals
A globally visible platform to publish scientific studies and a source of educational updates.
Publications
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Next Meetings
Lugano,
Switzerland
ESMO Preceptorship on Supportive and Palliative Care 2024: Lugano
Valencia,
Spain
ESMO Preceptorship on Colorectal Cancer 2024: Valencia
Berlin,
Germany
ESMO Breast Cancer 2024
Helsinki,
Finland
ESMO Preceptorship on NSCLC 2024: Helsinki
Sint Michielsgestel,
Netherlands
Methods in Clinical Cancer Research Workshop 2024
Florence,
Italy
ESMO Gynaecological Cancers Congress 2024
Munich,
Germany
ESMO Gastrointestinal Cancers Congress 2024
Lugano,
Switzerland
ESMO Preceptorship on Uterine Cancer 2024: Lugano
Munich,
Germany
ESMO Preceptorship on Breast Cancer 2024: Munich
Video Gallery
Career Development
Improve your career path
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
Are you looking for a fellowship not offered by ESMO or would like to post a fellowship?
ESMO Examination
ESMO Members: the main session of the ESMO Examination 2023 will be held on Saturday 21 October during the ESMO Congress 2023.
Membership
Become a Member
172
Countries35k +
Oncologyprofessionals
40+
Oncologyspecialties